The Immunobiology of Cancer Immunosurveillance and Immunoediting

Algarra, 2000, The HLA crossroad in tumor immunology, Hum. Immunol., 61, 65, 10.1016/S0198-8859(99)00156-1 Asea, 2002, Novel signal transduction pathway utilized by extracellular HSP70, J. Biol. Chem., 277, 15028, 10.1074/jbc.M200497200 Bach, 1997, The IFNγ receptor, Annu. Rev. Immunol., 15, 563, 10.1146/annurev.immunol.15.1.563 Bahram, 2000, MIC genes, Adv. Immunol., 76, 1, 10.1016/S0065-2776(01)76018-X Balkwill, F., and Mantovani, A. (2001). Inflammation and cancer: back to Virchow? Lancet 357 539–545. Bauer, 1999, Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA, Science, 285, 727, 10.1126/science.285.5428.727 Belardelli, 2002, Interferon-alpha in tumor immunity and immunotherapy, Cytokine Growth Factor Rev., 13, 119, 10.1016/S1359-6101(01)00022-3 Boon, 1996, Human tumor antigens recognized by T lymphocytes, J. Exp. Med., 183, 725, 10.1084/jem.183.3.725 Burnet, 1957, Cancer—a Biological Approach, BMJ, 1, 841, 10.1136/bmj.1.5023.841 Burnet, 1964, Immunological factors in the process of carcinogenesis, Br. Med. Bull., 20, 154, 10.1093/oxfordjournals.bmb.a070310 Burnet, 1970, The concept of immunological surveillance, Prog. Exp. Tumor Res., 13, 1, 10.1159/000386035 Burnet, 1971, Immunological surveillance in neoplasia, Transplant. Rev., 7, 3 Carayannopoulos, 2002, Cutting edge, J. Immunol., 169, 4079, 10.4049/jimmunol.169.8.4079 Cerwenka, 2001, Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo, Proc. Natl. Acad. Sci. USA, 98, 11521, 10.1073/pnas.201238598 Chalupny, 2003, ULBP4 is a novel ligand for human NKG2D, Biochem. Biophys. Res. Commun., 305, 129, 10.1016/S0006-291X(03)00714-9 Conejo-Garcia, 2003, Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells, Cancer Biol. Ther., 2, 446, 10.4161/cbt.2.4.479 Cosman, 2001, ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor, Immunity, 14, 123, 10.1016/S1074-7613(01)00095-4 Coussens, 2002, Inflammation and cancer, Nature, 420, 860, 10.1038/nature01322 Cretney, 2002, Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice, J. Immunol., 168, 1356, 10.4049/jimmunol.168.3.1356 Cui, 2003, Spontaneous regression of advanced cancer, Proc. Natl. Acad. Sci. USA, 100, 6682, 10.1073/pnas.1031601100 Das, 2001, MICA engagement by human Vγ2Vδ2 T cells enhances their antigen-dependent effector function, Immunity, 15, 83, 10.1016/S1074-7613(01)00168-6 Diefenbach, 2000, Ligands for the murine NKG2D receptor, Nat. Immunol., 1, 119, 10.1038/77793 Diefenbach, 2001, Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity, Nature, 413, 165, 10.1038/35093109 Diefenbach, 2003, A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity, Eur. J. Immunol., 33, 381, 10.1002/immu.200310012 Dighe, 1994, Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFNγ receptors, Immunity, 1, 447, 10.1016/1074-7613(94)90087-6 Dunn, 2004, The Three Es of Cancer Immunoediting, Annu. Rev. Immunol., 22, 329, 10.1146/annurev.immunol.22.012703.104803 Dunn, 2002, Cancer immunoediting, Nat. Immunol., 3, 991, 10.1038/ni1102-991 Dranoff, 2004, Cytokines in cancer pathogenesis and cancer therapy, Nat. Rev. Cancer, 4, 11, 10.1038/nrc1252 Ehrlich, 1909, Ueber den jetzigen Stand der Karzinomforschung, Ned. Tijdschr. Geneeskd., 5, 273 Elder, 1997, Remission of transplanted melanoma–clinical course and tumour cell characterisation, Clin. Transplant., 11, 565 Engel, 1996, Methylcholanthrene-induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression, APMIS, 104, 629, 10.1111/j.1699-0463.1996.tb04923.x Fallarino, 1999, Cutting edge, J. Immunol., 163, 4109, 10.4049/jimmunol.163.8.4109 Gao, 2003, γδ T cells provide an early source of interferon γ in tumor immunity, J. Exp. Med., 198, 433, 10.1084/jem.20030584 Gilfillan, 2002, NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation, Nat. Immunol., 3, 1150, 10.1038/ni857 Girardi, 2003, The distinct contributions of murine T cell receptor (TCR)γδ+ and TCRαβ+ T cells to different stages of chemically induced skin cancer, J. Exp. Med., 198, 747, 10.1084/jem.20021282 Girardi, 2001, Regulation of cutaneous malignancy by γδ T cells, Science, 294, 605, 10.1126/science.1063916 Gresser, 2002, Endogenous type I interferons as a defense against tumors, Cytokine Growth Factor Rev., 13, 111, 10.1016/S1359-6101(01)00035-1 Groh, 1996, Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium, Proc. Natl. Acad. Sci. USA, 93, 12445, 10.1073/pnas.93.22.12445 Groh, 1999, Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB, Proc. Natl. Acad. Sci. USA, 96, 6879, 10.1073/pnas.96.12.6879 Groh, 2001, Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells, Nat. Immunol., 2, 255, 10.1038/85321 Groh, 2002, Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation, Nature, 419, 734, 10.1038/nature01112 Hahn, 2002, Modelling the molecular circuitry of cancer, Nat. Rev. Cancer, 2, 331, 10.1038/nrc795 Hahn, 2002, Rules for making human tumor cells, N. Engl. J. Med., 347, 1593, 10.1056/NEJMra021902 Hayakawa, 2003, α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis, Proc. Natl. Acad. Sci. USA, 100, 9464, 10.1073/pnas.1630663100 Jager, 1997, Immunoselection in vivo, Int. J. Cancer, 71, 142, 10.1002/(SICI)1097-0215(19970410)71:2<142::AID-IJC3>3.0.CO;2-0 Janeway, 1989, Approaching the asymptote? Evolution and revolution in immunology, Cold Spring Harb. Symp. Quant. Biol., 54, 1, 10.1101/SQB.1989.054.01.003 Jinushi, 2003, Critical role of MHC class I-related chain A and B expression on IFN-α-stimulated dendritic cells in NK cell activation, J. Immunol., 170, 1249, 10.4049/jimmunol.170.3.1249 Jinushi, 2003, Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid, Int. J. Cancer, 104, 354, 10.1002/ijc.10966 Johnson, 2002, Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4, J. Immunol., 168, 5233, 10.4049/jimmunol.168.10.5233 Kaplan, 1998, Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice, Proc. Natl. Acad. Sci. USA, 95, 7556, 10.1073/pnas.95.13.7556 Khong, 2002, Natural selection of tumor variants in the generation of “tumor escape” phenotypes, Nat. Immunol., 3, 999, 10.1038/ni1102-999 Khong, 2004, Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient, J. Immunother., 27, 184, 10.1097/00002371-200405000-00002 Lengauer, 1998, Genetic instabilities in human cancers, Nature, 396, 643, 10.1038/25292 Liyanage, 2002, Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma, J. Immunol., 169, 2756, 10.4049/jimmunol.169.5.2756 Loeb, 1991, Mutator phenotype may be required for multistage carcinogenesis, Cancer Res., 51, 3075 Loeb, 2003, Multiple mutations and cancer, Proc. Natl. Acad. Sci. USA, 100, 776, 10.1073/pnas.0334858100 MacKie, 2003, Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery, N. Engl. J. Med., 348, 567, 10.1056/NEJM200302063480620 Marincola, 2000, Escape of human solid tumors from T-cell recognition, Adv. Immunol., 74, 181, 10.1016/S0065-2776(08)60911-6 Matzinger, 1994, Tolerance, danger, and the extended family, Annu. Rev. Immunol., 12, 991, 10.1146/annurev.iy.12.040194.005015 Nishikawa, 2003, CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses, Proc. Natl. Acad. Sci. USA, 100, 10902, 10.1073/pnas.1834479100 Nomura, 1994, Isolation and characterization of retinoic acid-inducible cDNA clones in F9 cells, Differentiation, 57, 39, 10.1046/j.1432-0436.1994.5710039.x Ohashi, 2000, Cutting edge, J. Immunol., 164, 558, 10.4049/jimmunol.164.2.558 Old, 2003, Cancer vaccines 2003, Cancer Immun., 3, 1 Old, 1964, Immunology of Experimental Tumors, Annu. Rev. Med., 15, 167, 10.1146/annurev.me.15.020164.001123 Onizuka, 1999, Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody, Cancer Res., 59, 3128 Pardoll, 2003, Does the immune system see tumors as foreign or self?, Annu. Rev. Immunol., 21, 807, 10.1146/annurev.immunol.21.120601.141135 Pende, 2002, Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes, Cancer Res., 62, 6178 Penn, 1991, Donor transmitted disease, Transplant. Proc., 23, 2629 Penn, 1996, Malignant melanoma in organ allograft recipients, Transplantation, 61, 274, 10.1097/00007890-199601270-00019 Radosavljevic, 2002, A cluster of ten novel MHC class I related genes on human chromosome 6q24.2-q25.3, Genomics, 79, 114, 10.1006/geno.2001.6673 Raulet, 2003, Roles of the NKG2D immunoreceptor and its ligands, Nat. Rev. Immunol., 3, 781, 10.1038/nri1199 Read, 1998, CD38+CD45RBlow CD4+ T cells, Eur. J. Immunol., 28, 3435, 10.1002/(SICI)1521-4141(199811)28:11<3435::AID-IMMU3435>3.0.CO;2-P Rosenberg, 1999, A new era for cancer immunotherapy based on the genes that encode cancer antigens, Immunity, 10, 281, 10.1016/S1074-7613(00)80028-X Rubinstein, 2004, Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege, Cancer Cell, 5, 241, 10.1016/S1535-6108(04)00024-8 Sahin, 1995, Human neoplasms elicit multiple specific immune responses in the autologous host, Proc. Natl. Acad. Sci. USA, 92, 11810, 10.1073/pnas.92.25.11810 Sakaguchi, 1995, Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases, J. Immunol., 155, 1151, 10.4049/jimmunol.155.3.1151 Schreiber, 2004, Response to `A cancer immunosurveillance controversy', Nat. Immunol., 5, 4, 10.1038/ni0104-4 Seliger, 2000, Antigen-processing machinery breakdown and tumor growth, Immunol. Today, 21, 455, 10.1016/S0167-5699(00)01692-3 Seong, 2004, Hydrophobicity, Nat. Rev. Immunol., 4, 469, 10.1038/nri1372 Shankaran, 2001, IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity, Nature, 410, 1107, 10.1038/35074122 Shi, 2003, Molecular identification of a danger signal that alerts the immune system to dying cells, Nature, 425, 516, 10.1038/nature01991 Shimizu, 1999, Induction of tumor immunity by removing CD25+CD4+ T cells, J. Immunol., 163, 5211, 10.4049/jimmunol.163.10.5211 Shinkai, 1992, RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement, Cell, 68, 855, 10.1016/0092-8674(92)90029-C Smyth, 2001, NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma, Int. Immunol., 13, 459, 10.1093/intimm/13.4.459 Smyth, 2001, A fresh look at tumor immunosurveillance and immunotherapy, Nat. Immunol., 2, 293, 10.1038/86297 Smyth, 2003, Nature's TRAIL–on a path to cancer immunotherapy, Immunity, 18, 1, 10.1016/S1074-7613(02)00502-2 Smyth, 2000, Differential tumor surveillance by natural killer (NK) and NKT cells, J. Exp. Med., 191, 661, 10.1084/jem.191.4.661 Smyth, 2000, Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma, J. Exp. Med., 192, 755, 10.1084/jem.192.5.755 Srivastava, 2002, Interaction of heat shock proteins with peptides and antigen presenting cells, Annu. Rev. Immunol., 20, 395, 10.1146/annurev.immunol.20.100301.064801 Street, 2001, Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis, Blood, 97, 192, 10.1182/blood.V97.1.192 Street, 2002, Suppression of lymphoma and epithelial malignancies effected by interferon γ, J. Exp. Med., 196, 129, 10.1084/jem.20020063 Street, 2004, Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and γδ T cells, J. Exp. Med., 199, 879, 10.1084/jem.20031981 Stutman, 1974, Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice, Science, 183, 534, 10.1126/science.183.4124.534 Stutman, 1979, Chemical carcinogenesis in nude mice, J. Natl. Cancer Inst., 2, 353 Suranyi, 1998, Advanced donor-origin melanoma in a renal transplant recipient, Transplantation, 66, 655, 10.1097/00007890-199809150-00020 Svane, 1996, Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice, Eur. J. Immunol., 26, 1844, 10.1002/eji.1830260827 Takaoka, 2003, Integration of interferon-α/β signaling to p53 responses in tumour suppression and antiviral defence, Nature, 424, 516, 10.1038/nature01850 Takeda, 2002, Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development, J. Exp. Med., 195, 161, 10.1084/jem.20011171 Terabe, 2004, Immunoregulatory T cells in tumor immunity, Curr. Opin. Immunol., 16, 157, 10.1016/j.coi.2004.01.010 Terabe, 2000, NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway, Nat. Immunol., 1, 515, 10.1038/82771 Termeer, 2002, Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4, J. Exp. Med., 195, 99, 10.1084/jem.20001858 Thomas, 1959, Discussion, 529 Thomas, 1982, On immunosurveillance in human cancer, Yale J. Biol. Med., 55, 329 Thornton, 1998, CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production, J. Exp. Med., 188, 287, 10.1084/jem.188.2.287 Tieng, 2002, Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA, Proc. Natl. Acad. Sci. USA, 99, 2977, 10.1073/pnas.032668099 Uhr, 1991, Cancer dormancy, Cancer Res., 51, 5045s Uyttenhove, 2003, Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase, Nat. Med., 9, 1269, 10.1038/nm934 van den Broek, 1996, Decreased tumor surveillance in perforin-deficient mice, J. Exp. Med., 184, 1781, 10.1084/jem.184.5.1781 van der Bruggen, 1991, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science, 254, 1643, 10.1126/science.1840703 Vetter, 2002, Expression of stress-induced MHC class I related chain molecules on human melanoma, J. Invest. Dermatol., 118, 600, 10.1046/j.1523-1747.2002.01700.x Wang, 2004, Tumor-specific human CD4+ regulatory T cells and their ligands, Immunity, 20, 107, 10.1016/S1074-7613(03)00359-5 Wang, 2003, Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells, Nat. Med., 10, 48, 10.1038/nm976 Wheelock, 1981, The tumor dormant state, Adv. Cancer Res., 34, 107, 10.1016/S0065-230X(08)60240-7 Wong, 1997, Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3γ, J. Biol. Chem., 272, 28779, 10.1074/jbc.272.45.28779 Woo, 2001, Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer, Cancer Res., 61, 4766 Wu, 1997, KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene, Nat. Genet., 17, 141, 10.1038/ng1097-141 Wu, 1999, Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor, Cancer Res., 59, 2770 Yee, 2002, Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma, Proc. Natl. Acad. Sci. USA, 99, 16168, 10.1073/pnas.242600099